[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE484517T1 - Höhe konstitutive produktion von anthrax oberflächenschutzantigen - Google Patents

Höhe konstitutive produktion von anthrax oberflächenschutzantigen

Info

Publication number
ATE484517T1
ATE484517T1 AT01274653T AT01274653T ATE484517T1 AT E484517 T1 ATE484517 T1 AT E484517T1 AT 01274653 T AT01274653 T AT 01274653T AT 01274653 T AT01274653 T AT 01274653T AT E484517 T1 ATE484517 T1 AT E484517T1
Authority
AT
Austria
Prior art keywords
cells
anthrax
coli
followed
surface protection
Prior art date
Application number
AT01274653T
Other languages
English (en)
Inventor
Rakesh Bhatnagar
Syed Moshin Waheed
Vibha Chauhan
Original Assignee
Rakesh Bhatnagar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakesh Bhatnagar filed Critical Rakesh Bhatnagar
Application granted granted Critical
Publication of ATE484517T1 publication Critical patent/ATE484517T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Laminated Bodies (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT01274653T 2001-11-05 2001-12-07 Höhe konstitutive produktion von anthrax oberflächenschutzantigen ATE484517T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1127DE2001 IN190590B (de) 2001-11-05 2001-11-05
PCT/IN2001/000215 WO2003040179A1 (en) 2001-11-05 2001-12-07 High level constitutive production of anthrax protective antigen

Publications (1)

Publication Number Publication Date
ATE484517T1 true ATE484517T1 (de) 2010-10-15

Family

ID=11097131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274653T ATE484517T1 (de) 2001-11-05 2001-12-07 Höhe konstitutive produktion von anthrax oberflächenschutzantigen

Country Status (16)

Country Link
US (1) US7329513B2 (de)
EP (1) EP1442052B1 (de)
JP (1) JP2005510215A (de)
CN (1) CN100347189C (de)
AT (1) ATE484517T1 (de)
BR (1) BRPI0117173A2 (de)
CA (1) CA2465679A1 (de)
DE (1) DE60143276D1 (de)
HK (1) HK1072610A1 (de)
IL (1) IL161725A0 (de)
IN (1) IN190590B (de)
MX (1) MXPA04004281A (de)
RU (1) RU2288272C2 (de)
UA (1) UA80809C2 (de)
WO (1) WO2003040179A1 (de)
ZA (1) ZA200403396B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80809C2 (en) * 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
WO2004108750A1 (en) * 2003-06-06 2004-12-16 Avecia Limited Process for the separation of proteins
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
EP1919504B1 (de) 2005-08-03 2013-10-16 iBio, Inc. Antikörper gegen bacillus anthracis protektiv antigen
EP1984405A4 (de) 2006-02-13 2010-06-30 Fraunhofer Usa Inc Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
GB0607462D0 (en) * 2006-04-13 2006-05-24 Avecia Ltd Assay
WO2007145760A2 (en) * 2006-05-12 2007-12-21 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
US8420607B2 (en) 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
AU2007349310B2 (en) 2006-06-30 2013-03-14 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS OF DISEASE CONTROL AND PREVENTION (WASHINGTON D.C.) Anthrax carbohydrates,synthesis and uses thereof
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009126355A2 (en) * 2008-01-28 2009-10-15 Baxter International, Inc. Methods of increasing recombinant production of bacillus anthracis protective antigen
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
CA2738621C (en) 2008-10-02 2017-01-31 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US20120301951A1 (en) * 2010-11-18 2012-11-29 E. I. Du Pont De Nemours And Company Prevention of contamination of nutrient feed reservoirs & feed lines in bioreactor systems
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
CN115125224B (zh) * 2022-08-11 2023-07-18 福州大学 一种可规模化生产具有活性的dna聚合酶的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800821A (en) * 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
WO1999051733A2 (en) * 1998-04-07 1999-10-14 Wisconsin Alumni Research Foundation Enterotoxin-deficient bacillus
US20020086032A1 (en) * 1999-02-02 2002-07-04 Mahan Michael J. Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
US7193126B2 (en) * 2001-10-01 2007-03-20 The Regents Of The University Of California Method for generating overexpression of alleles in genes of unknown function
UA80809C2 (en) * 2001-11-05 2007-11-12 Process for preparation of protective antigen protein of anthracis with e.coli
US7763451B2 (en) * 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines

Also Published As

Publication number Publication date
RU2288272C2 (ru) 2006-11-27
DE60143276D1 (de) 2010-11-25
JP2005510215A (ja) 2005-04-21
US20050054038A1 (en) 2005-03-10
IN190590B (de) 2003-08-09
EP1442052A1 (de) 2004-08-04
WO2003040179A1 (en) 2003-05-15
UA80809C2 (en) 2007-11-12
RU2004117085A (ru) 2005-03-27
ZA200403396B (en) 2005-08-05
EP1442052B1 (de) 2010-10-13
BRPI0117173A2 (pt) 2018-04-17
MXPA04004281A (es) 2005-03-31
CA2465679A1 (en) 2003-05-15
CN100347189C (zh) 2007-11-07
CN1582298A (zh) 2005-02-16
IL161725A0 (en) 2005-11-20
HK1072610A1 (en) 2005-09-02
US7329513B2 (en) 2008-02-12

Similar Documents

Publication Publication Date Title
ATE484517T1 (de) Höhe konstitutive produktion von anthrax oberflächenschutzantigen
Niemer et al. The human anti‐HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: down‐regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant‐based expression platforms
CY1110494T1 (el) Μεταστροφες μεταβολικου ρυθμου σε ζυμωσεις που εκφραζουν ανασυνδυασμενες πρωτεϊνες
CA2417415A1 (en) Expression of biologically active polypeptides in duckweed
EP0737747A3 (de) Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragment-Fusionsmolekülen in E. coli
CN102533839B (zh) 融合表达含有二硫键蛋白质的方法
GB9810999D0 (en) Materials and methods relating to the expression of genes
EA200600554A1 (ru) Способ получения рекомбинантных белков
CN102659928A (zh) 一种人工合成的信号肽及其应用
Kawasaki et al. Folding-Dependentin VitroProtein Splicing of theSaccharomyces cerevisiae VMA1Protozyme
CN104151407B (zh) 一种制备人妊娠特异性糖蛋白9的方法
WO2007015691A3 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
CN101921315B (zh) 一种人工合成的信号肽及其应用
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
CN104846001B (zh) 一种外源蛋白原核分泌表达系统及其应用
CN107384934A (zh) 重组人干扰素α2b的制备方法
CA2082802C (en) Method for expressing polypeptides in cyanobacteria
Kunes et al. Expression of antibodies using single‐open reading frame vector design and polyprotein processing from mammalian cells
RU2230781C1 (ru) Штамм дрожжей saccharomyces cerevisiae 1-60-д578 (msil), - продуцент рекомбинантного интерлейкина-2 человека и способ его получения
RU2315105C1 (ru) ШТАММ ДРОЖЖЕЙ PICHIA PASTORIS PS107(pPIC9HAbIL-2), ЯВЛЯЮЩИЙСЯ ПРОДУЦЕНТОМ ГИБРИДНОГО БЕЛКА, СОСТОЯЩЕГО ИЗ АЛЬБУМИНА ПЛАЗМЫ КРОВИ ЧЕЛОВЕКА И ИНТЕРЛЕЙКИНА-2 ЧЕЛОВЕКА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pPIC9HAbIL-2 И СПОСОБ ЕЕ КОНСТРУИРОВАНИЯ
DE69427403D1 (de) Peptide-familie, genannt xenoxine
Schendel Overview of Protein Expression in E. coli
JPH02437A (ja) Ｅ・コリーの配列特異的酸性プロテアーゼ
PT801682E (pt) Processo para a producao de proteinas
Esipov et al. Recombinant Thymosin α1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties